Subscribe to newsletter

UrbanObserver

https://demo.afthemes.com/newsphere/fashion/wp-content/uploads/sites/2/2019/04/cropped-af-themes-main-dark.png

Always Active
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

No cookies to display.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

No cookies to display.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

No cookies to display.

Monday, March 17, 2025

Top 5 This Week

Related Posts

Pfizer confirms interest in AstraZeneca takeover

Pfizer has confirmed it has contacted AstraZeneca over a possible multi-billion dollar takeover.

The pharmaceutical said it made an initial approach in January, but after “limited high-level discussions” AstraZeneca discontinued the talks on January 14.

However, it said recent market developments had prompted it to approach AstraZeneca for a second time.

Pfizer has confirmed it has contacted AstraZeneca over a possible multi-billion dollar takeover
Pfizer has confirmed it has contacted AstraZeneca over a possible multi-billion dollar takeover

“AstraZeneca again declined to engage. Pfizer is currently considering its options,” Pfizer said in a statement.

Pfizer said its initial offer in January was a combination of cash and shares worth $75 per AstraZeneca share, worth $94 billion in total.

At the time, it represented a 30% premium to AstraZeneca’s share price, although AstraZeneca’s share price has since increased and on Monday morning it jumped nearly 15% .

Pfizer said the deal was “a highly compelling opportunity” for AstraZeneca’s shareholders.

It said if the takeover went through, the combined firm would have management in both the US and the UK, but would list its shares on the New York Stock Exchange.

“We have great respect for AstraZeneca and its proud heritage,” said Pfizer chairman and chief executive Ian Read.

Pfizer said it would only make a firm offer if AstraZeneca directors voted unanimously in favor of the deal.

“The strategic, business and financial rationale for a transaction is compelling,” it added.

Buying AstraZeneca would give Pfizer, which makes Viagra among other drugs, access to a number of cancer and diabetes drugs.

Clyde K. Valle
Clyde K. Valle
Clyde is a business graduate interested in writing about latest news in politics and business. He enjoys writing and is about to publish his first book. He’s a pet lover and likes to spend time with family. When the time allows he likes to go fishing waiting for the muse to come.

Popular Articles